TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$16.92
0.02 (0.12%)
▲
5d:
-0.53%
30d:
+2.61%
90d:
+2.55%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
26d
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 20.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 20.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.70
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $16.92, which is considered fair relative to its 30-day fair value range of $16.49 to $17.16. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.1) compared to its historical average (12.1). At these levels, the market is pricing in 20.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is showing sideways momentum. The price is currently testing key support at $16.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TBPH is showing sideways momentum. The price is currently testing key support at $16.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$16.49 -
$17.16
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.67)
- NEUTRAL: Trading at premium valuation - market expects 20.5% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$16.49 -
$17.16
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$16.89
Resistance Level
$17.28
Current Trend
Sideways
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.15
Wall Street Target
$17.67
(+4.4%)
Revenue Growth (YoY)
15.0%
Profit Margin
104.3%
Valuation Premium vs History
+20.5% premium
PE vs Historical
21.2 vs 12.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+20.5%
(market-implied from PE analysis)
1-Year Target
$20.39
(+21%)
2-Year Target
$24.57
(+45%)
3-Year Target
$29.60
(+75%)
3-Yr Target (if PE normalizes)
(PE: 21→12)
PE COMPRESSION
$16.94
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 281.0%)
$58.81
(+248%)
Base:
(SPY PE: 21.2, Growth: 281.0%)
$57.11
(+238%)
Bear:
(PE: 12.1, Growth: 281.0%)
$32.67
(+93%)
📈
Valuation based on Current Earnings
Trailing PE: 7.59 | Current EPS (TTM): $2.23
Bull Case
$9.31
(-45%)
Analyst growth -50.0%, PE expands to 8.4
Base Case
$8.46
(-50%)
Market implied -50.0%, PE stable at 7.6
Bear Case
$11.51
(-32%)
Severe decline -20.0%, PE contracts to 6.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 8:09 PM ET
Data refreshes hourly during market hours. Next update: 9:08 PM
Data refreshes hourly during market hours. Next update: 9:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
